Today, Piretanide is a topic of great relevance and interest to a wide audience. With the advancement of technology and globalization, Piretanide has taken a leading role in today's society, generating multiple debates, discussions and developments in different areas. From academia and science to business and politics, Piretanide has captured the attention of experts and fans alike. In this article, we will explore the different facets and dimensions of Piretanide, analyzing its impact and relevance in the current context. Without a doubt, Piretanide is a topic that deserves to be delved into and discussed in depth.
![]() | |
Clinical data | |
---|---|
Trade names | Arelix, Eurelix, Tauliz, others |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ~90%[2] |
Protein binding | 96% |
Metabolism | not identified |
Excretion | Urine (60%), feces (40%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.054.394 |
Chemical and physical data | |
Formula | C17H18N2O5S |
Molar mass | 362.40 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Piretanide is a loop diuretic[3] compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as furosemide and bumetanide found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to studies in man and finally to the introduction as a saluretic and antihypertensive[4] medication in Germany, France, Italy and other countries.
It was made in 1973, patented in 1974, and approved for medical use in 1981.[5]
Brand names include Arelix, Eurelix, Tauliz.